State Opioid Response Grants funding
Substance Abuse and Mental Health Block Grant funding
H.R. 2379 The State Opioid Response Grant Authorization Act of 2021
Appropriations funding for Fiscal Year 2022 - Further Extending Government Funding Act
NDAA for Fiscal Year 2022- provisions related to biological and chemical defense and access to naloxone
S.4231 - Preparing for the Next Pandemic Act
HR 3263 Outreach - DHS Medical Countermeasures Act
- H.R. 4341; S. 987 - CARA 3. - Comprehensive Addiction and Recovery Act
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines
H.R 2366 S.1457 - Stop Fentanyl Act
H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021
Issues related to the development, manufacture, and distribution of coronavirus vaccines.
Duration: January 1, 2019
to
December 31, 2021
General Issues: Budget/Appropriations , Defense , Health Issues , Alcohol & Drug Abuse , Homeland Security , Disaster Planning/Emergencies
Spending: about $360,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2019: U.S. Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2021
DOTCHIN & ASSOCIATES, LLC terminated an engagement in which they represented Emergent Biosolutions on Jan. 18, 2022.
Original Filing: 301325396.xml
Lobbying Issues
State Opioid Response Grants funding
Substance Abuse and Mental Health Block Grant funding
H.R. 2379 The State Opioid Response Grant Authorization Act of 2021
Appropriations funding for Fiscal Year 2022 - Further Extending Government Funding Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
NDAA for Fiscal Year 2022- provisions related to biological and chemical defense and access to naloxone
Agencies Lobbied
U.S. Senate
Lobbying Issues
S.4231 - Preparing for the Next Pandemic Act
HR 3263 Outreach - DHS Medical Countermeasures Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
- H.R. 4341; S. 987 - CARA 3. - Comprehensive Addiction and Recovery Act
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines
H.R 2366 S.1457 - Stop Fentanyl Act
H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021
Issues related to the development, manufacture, and distribution of coronavirus vaccines.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, DOTCHIN & ASSOCIATES, LLC lobbied for Emergent Biosolutions , earning $30,000. The report was filed on Oct. 19, 2021.
Original Filing: 301303342.xml
Lobbying Issues
State Opioid Response Grants funding
Substance Abuse and Mental Health Block Grant funding
H.R. 2379 The State Opioid Response Grant Authorization Act of 2021
Appropriations funding for Fiscal Year 2022
Agencies Lobbied
U.S. Senate
Lobbying Issues
NDAA for Fiscal Year 2022- provisions related to biological and chemical defense and access to naloxone
Agencies Lobbied
U.S. Senate
Lobbying Issues
S.4231 - Preparing for the Next Pandemic Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
CARA 3.0 - Comprehensive Addiction and Recovery Act
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines
H.R 2366 S.1457 - Stop Fentanyl Act
H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021
Issues related to the development, manufacture, and distribution of coronavirus vaccines.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, DOTCHIN & ASSOCIATES, LLC lobbied for Emergent Biosolutions , earning $30,000. The report was filed on July 18, 2021.
Original Filing: 301279215.xml
Lobbying Issues
State Opioid Response Grants funding
Substance Abuse and Mental Health Block Grant funding
H.R. 2379 The State Opioid Response Grant Authorization Act of 2021
Appropriations funding for Fiscal Year 2022
Agencies Lobbied
U.S. Senate
Lobbying Issues
NDAA for Fiscal Year 2022- provisions related to biological and chemical defense and access to naloxone
Agencies Lobbied
U.S. Senate
Lobbying Issues
S.4231 - Preparing for the Next Pandemic Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
CARA 3.0 - Comprehensive Addiction and Recovery Act
Emergency Support for Substance Use Disorders Act/ Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines
H.R. 2379 The State Opioid Response Grant Authorization Act of 2021
H.R 2366 S.1457 - Stop Fentanyl Act
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, DOTCHIN & ASSOCIATES, LLC lobbied for Emergent Biosolutions , earning $30,000. The report was filed on April 16, 2021.
Original Filing: 301253938.xml
Lobbying Issues
State Opioid Response Grants funding
Substance Abuse and Mental Health Block Grant funding
H.R. 2379 The State Opioid Response Grant Authorization Act of 2021
Appropriations funding for Fiscal Year 2022
Agencies Lobbied
U.S. Senate
Lobbying Issues
NDAA for Fiscal Year 2022- provisions related to biological and chemical defense and access to naloxone
Agencies Lobbied
U.S. Senate
Lobbying Issues
S.4231 - Preparing for the Next Pandemic Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
CARA 3.0 - Comprehensive Addiction and Recovery Act
Emergency Support for Substance Use Disorders Act/ Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, DOTCHIN & ASSOCIATES, LLC lobbied for Emergent Biosolutions , earning $30,000. The report was filed on Jan. 18, 2021.
Original Filing: 301233527.xml
Lobbying Issues
HR 8406 - Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act)
State Opioid Response Grants funding for 2021
Emergency support for substance use disorders act/legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder
HR 2466 - The State Opioid Response Grant Authorization Act
HEALS Act
H.R. 133, Consolidated Appropriations Act 2021
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 6395, NDAA for Fiscal Year 2021- provisions related to biological and chemical defense and access to naloxone
HR 7574 - Strengthening America's Strategic National Stockpile Act of 2020, as amended (Rep. Slotkin - Energy & Commerce)
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 7783, Plasma Donation Awareness Act of 2020" co-sponsored by Rep. Scott Peters and Rep. Brad Wenstrup, and S. 4179, "Plasma Donation Awareness Act co-sponsored by Sen. Amy Klobuchar and Sen. Roger Wicker that would simply add plasma to a blood donation awareness campaign
HEROES Act - H.R.8406 - The Heroes Act
S.4231 - Preparing for the Next Pandemic Act
H.R. 14, the Commitment to Defeat the Virus and Keep America Healthy Act
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines
Agencies Lobbied
U.S. Senate
Lobbying Issues
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, DOTCHIN & ASSOCIATES, LLC lobbied for Emergent Biosolutions , earning $30,000. The report was filed on Oct. 20, 2020.
Original Filing: 301219731.xml
Lobbying Issues
Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act), FY 2021 and COVID-19 next supplemental provisions related to development, aquisition and stockpiling of medical countermeasures for the U.S. Government
State Opioid Response Grants funding for 2021
Emergency support for substance use disorders act/legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder
HR 2466 - The State Opioid Response Grant Authorization Act
HEALS Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
NDAA - provisions related to biological and chemical defense
HR 7574 - Strengthening America's Strategic National Stockpile Act of 2020, as amended (Rep. Slotkin - Energy & Commerce)
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 7783, Plasma Donation Awareness Act of 2020" co-sponsored by Rep. Scott Peters and Rep. Brad Wenstrup, and S. 4179, "Plasma Donation Awareness Act co-sponsored by Sen. Amy Klobuchar and Sen. Roger Wicker that would simply add plasma to a blood donation awareness campaign
HEROES Act - H.R.8406 - The Heroes Act
S.4231 - Preparing for the Next Pandemic Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, DOTCHIN & ASSOCIATES, LLC lobbied for Emergent Biosolutions , earning $30,000. The report was filed on July 16, 2020.
Original Filing: 301189300.xml
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Department of Defense appropriations for Medical Countermeasures
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, S.3548 - CARES Act, FY 2021 Appropriations
provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
NDAA - provisions related to biological and chemical defense
Issues related to Priority Review Voucher programs
Opioid and heroin addiction legislation, naloxone access, co- prescribing/opioid prescribing guidelines
Agencies Lobbied
U.S. Senate
Lobbying Issues
NDAA - provisions related to biological and chemical defense
Department of Defense appropriations for Medical Countermeasures
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, S.3548 - CARES Act, FY 2021 Appropriations
provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
NDAA - provisions related to biological and chemical defense
Issues related to Priority Review Voucher programs
Opioid and heroin addiction legislation, naloxone access, co- prescribing/opioid prescribing guidelines
Agencies Lobbied
U.S. Senate
Type of Issue
Homeland Security/Emergencies
Lobbying Issues
FDA regulatory issues
Issues related to Priority Review Voucher programs
Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act), FY 2021 and Covid-19 next supplemental provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
State Opioid Response Grants funding for FY 2021
Emergency Support for Substance Use Disorders Act/ Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, DOTCHIN & ASSOCIATES, LLC lobbied for Emergent Biosolutions , earning $30,000. The report was filed on April 20, 2020.
Original Filing: 301175464.xml
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Department of Defense appropriations for Medical Countermeasures
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, S.3548 - CARES Act, FY 2021 Appropriations
provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
NDAA - provisions related to biological and chemical defense
Issues related to Priority Review Voucher programs
Opioid and heroin addiction legislation, naloxone access, co- prescribing/opioid prescribing guidelines
Agencies Lobbied
U.S. Senate
Lobbying Issues
NDAA - provisions related to biological and chemical defense
Department of Defense appropriations for Medical Countermeasures
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, S.3548 - CARES Act, FY 2021 Appropriations
provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
NDAA - provisions related to biological and chemical defense
Issues related to Priority Review Voucher programs
Opioid and heroin addiction legislation, naloxone access, co- prescribing/opioid prescribing guidelines
Agencies Lobbied
U.S. Senate
Type of Issue
Homeland Security/Emergencies
Lobbying Issues
FDA regulatory issues
Issues related to Priority Review Voucher programs
Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, DOTCHIN & ASSOCIATES, LLC lobbied for Emergent Biosolutions , earning $30,000. The report was filed on Jan. 15, 2020.
Original Filing: 301106022.xml
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Department of Defense appropriations for Medical Countermeasures
Agencies Lobbied
U.S. Senate
Lobbying Issues
NDAA - provisions related to biological and chemical defense
Department of Defense appropriations for Medical Countermeasures
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Agencies Lobbied
U.S. Senate
Type of Issue
Homeland Security/Emergencies
Lobbying Issues
FDA regulatory issues
Issues related to Priority Review Voucher programs
Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, DOTCHIN & ASSOCIATES, LLC lobbied for Emergent Biosolutions , earning $30,000. The report was filed on Oct. 21, 2019.
Original Filing: 301073689.xml
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Department of Defense appropriations for Medical Countermeasures
Agencies Lobbied
U.S. Senate
Lobbying Issues
NDAA - provisions related to biological and chemical defense
Department of Defense appropriations for Medical Countermeasures
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Agencies Lobbied
U.S. Senate
Type of Issue
Homeland Security/Emergencies
Lobbying Issues
FDA regulatory issues
Issues related to Priority Review Voucher programs
Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, DOTCHIN & ASSOCIATES, LLC lobbied for Emergent Biosolutions , earning $30,000. The report was filed on July 16, 2019.
Original Filing: 301046374.xml
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Department of Defense appropriations for Medical Countermeasures
Agencies Lobbied
U.S. Senate
Lobbying Issues
NDAA - provisions related to biological and chemical defense
Department of Defense appropriations for Medical Countermeasures
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Agencies Lobbied
U.S. Senate
Type of Issue
Homeland Security/Emergencies
Lobbying Issues
FDA regulatory issues
Issues related to Priority Review Voucher programs
Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, DOTCHIN & ASSOCIATES, LLC lobbied for Emergent Biosolutions , earning $30,000. The report was filed on April 22, 2019.
Original Filing: 301033659.xml
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Department of Defense appropriations for Medical Countermeasures
Agencies Lobbied
U.S. Senate
Lobbying Issues
NDAA - provisions related to biological and chemical defense
Department of Defense appropriations for Medical Countermeasures
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Agencies Lobbied
U.S. Senate
Type of Issue
Homeland Security/Emergencies
Lobbying Issues
FDA regulatory issues
Issues related to Priority Review Voucher programs
Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
DOTCHIN & ASSOCIATES, LLC filed a lobbying registration on March 4, 2019 to represent Emergent Biosolutions, effective Jan. 1, 2019.
Original Filing: 301021078.xml
Issue(s) they said they’d lobby about: FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act; NDAA - provisions related to biological and chemical defense .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...